Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ceritinib (LDK378) 是一种选择性,具有口服活性的、ATP 竞争性的 ALK 酪氨酸激酶抑制剂,IC50=200 pM。 它还抑制 IGF-1R (IC50:8 nM),InsR (IC50:7 nM) 和 STK22D (IC50:23 nM)。它显示出良好抗肿瘤效力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 397 | 现货 | ||
10 mg | ¥ 573 | 现货 | ||
50 mg | ¥ 832 | 现货 | ||
100 mg | ¥ 1,263 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 497 | 现货 |
产品描述 | Ceritinib (LDK378) is a specific ALK inhibitor (IC50: 0.2 nM). |
靶点活性 | ALK:0.2 nM (cell free), STK22D:23 nM (cell free), IGF-1R:8 nM (cell free), Insulin receptor:7 nM (cell free) |
体外活性 | Ceritinib (LDK378) also inhibits RET (IC50: 400 nM), FGFR3 (IC50: 430 nM), LCK (IC50: 560 nM), JAK2 (IC50: 610 nM), Aurora (IC50: 660 nM), LYN (IC50: 840 nM), EGFR (IC50: 900 nM), and FGFR4 (IC50: 950 nM) [1]. In ALK-positive cell line models, ceritinib was able to effectively inhibit ALK harboring the crizotinib-resistant mutations L1196M, G1269A, I1171T, and S1206Y, but it was ineffective at inhibiting ALK containing the G1202R and F1174C mutations.49 Among a panel of 46 other tested kinases, ceritinib showed strong activity only against IGF-1R (IC50: 8 nM), INSR (IC50: 7 nM), and STK22D (IC50: 23 nM) [2]. |
体内活性 | Mice treated with ceritinib at 50 mg/kg remained in complete remission with no discernible tumor growth for 4 months. In the mice treated with ceritinib at 25 mg/kg, tumor re-growth was observed in 4 out of 8 animals after 1 month, whereas complete remission was maintained in the other 4 animals for 4 months. In a primary explant model derived from a crizotinib-na?ve NSCLC tumor MGH006, treatment with 25 mg/kg ceritinib also led to tumor regressions [3]. |
激酶实验 | All kinases were expressed as either Histidine- or GST-tagged fusion proteins using the baculovirus expression technology except for the untagged ERK2 which was produced in E. coli. The kinase activity was measured in the LabChip mobility-shift assay. The assay was performed at 30°C for 60 min. The effect of the compound on the enzymatic activity was obtained from the linear progress curves in the absence and presence of compound and routinely determined from one reading (end point measurement) [1]. |
细胞实验 | Luciferase-expressing cells were incubated with serial dilutions of compounds or DMSO for 2–3 days. Luciferase expression was used as a measure of cell proliferation/survival and was evaluated with the Bright-Glo Luciferase Assay System. IC50 values were generated by using XLFit software [1]. |
动物实验 | SCID beige mice for crizotinib-resistant H2228 xenograft tumor models, nude mice for MGH006 primary explants and MGH045 cells were randomized into groups of 5, 6 or 8 mice with an average tumor volume of ~150 mm^3 and received Crizotinib or ceritinib daily treatments by oral gavage as indicated in each study. Tumor volumes were determined by using caliper measurements and calculated with the formula (Length × Width × Height)/2 [3]. |
别名 | 色瑞替尼, LDK378 |
分子量 | 558.14 |
分子式 | C28H36ClN5O3S |
CAS No. | 1032900-25-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 16 mg/mL (28.7 mM)
Ethanol: 3 mg/mL (5.37 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.7917 mL | 8.9583 mL | 17.9167 mL | 44.7916 mL |
5 mM | 0.3583 mL | 1.7917 mL | 3.5833 mL | 8.9583 mL | |
DMSO | 10 mM | 0.1792 mL | 0.8958 mL | 1.7917 mL | 4.4792 mL |
20 mM | 0.0896 mL | 0.4479 mL | 0.8958 mL | 2.2396 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ceritinib 1032900-25-6 Angiogenesis Proteases/Proteasome Tyrosine Kinase/Adaptors Serine Protease IGF-1R ALK 色瑞替尼 Anaplastic lymphoma kinase (ALK) inhibit Insulin Receptor Cluster of differentiation 246 CD246 LDK 378 LDK378 LDK-378 ALK tyrosine kinase receptor Anaplastic lymphoma kinase Inhibitor inhibitor